|
Forecast
Period
|
2024-2028
|
|
Market
Size (2022)
|
USD1.73
billion
|
|
CAGR
(2023-2028)
|
16.25%
|
|
Fastest
Growing Segment
|
Bioreactors/Fermenters
|
|
Largest
Market
|
China
|
Market Overview
Asia Pacific Cell and Gene Therapy Biomanufacturing
Market has valued at USD1.73 billion in 2022 and is anticipated to project
robust growth in the forecast period with a CAGR of 16.25% through 2028. Cell
and gene therapies (CGTs) are at the forefront of medical science,
revolutionizing the treatment landscape for diseases once considered incurable.
By modifying the genetic material within a patient's cells, these therapies
hold the potential to deliver long-lasting and even curative effects, paving
the way for a new era in healthcare.
In the realm of biomanufacturing, automation
emerges as a game-changer, augmenting efficiency and minimizing human error.
Additionally, artificial intelligence (AI) lends its expertise in areas such as
data analysis, predictive modeling, and optimizing manufacturing processes,
further enhancing the overall productivity of the industry.
Despite the remarkable progress in this field,
several challenges persist. Regulatory hurdles, the high cost of therapies, and
the intricacies of manufacturing pose significant obstacles that necessitate
careful attention to ensure sustainable market development and accessibility.
The rapid growth of the APAC Cell and Gene Therapy
Biomanufacturing Market is a testament to the region's unwavering commitment to
advancing healthcare and its embrace of innovative technologies. With ongoing
research and development activities, the APAC region is poised to emerge as a
major global player in the dynamic and promising field of cell and gene
therapy.
Key Market Drivers
Growing Prevalence of Chronic Diseases
Chronic diseases such as cancer, diabetes,
cardiovascular disorders, and neurodegenerative diseases pose a significant
health concern in the APAC region. The World Health Organization highlights
that non-communicable diseases, predominantly chronic in nature, account for a
staggering 80% of all deaths in the Western Pacific region. This alarming trend
underscores the pressing need for innovative and effective treatments, thereby
propelling the growth of the cell and gene therapy biomanufacturing market.
Cell and gene therapies (CGTs) emerge as a
revolutionary approach to address these chronic diseases comprehensively. By
precisely modifying a patient's genetic material, CGTs hold the potential to
not only manage symptoms but also fundamentally alter disease progression, and
in some cases, even effect cures. The transformative promise of CGTs has
garnered immense attention and interest within the medical community and beyond.
Biomanufacturing of CGTs is an intricate and
multifaceted process that demands substantial investment in research and
development, highly specialized equipment, and a skilled workforce. Recognizing
the immense potential of cell and gene therapies, the APAC region has
demonstrated a steadfast commitment to this burgeoning field. Countries like
China and South Korea have made substantial investments in CGT research and
biomanufacturing infrastructure, positioning themselves as leaders in this
transformative domain.
In conclusion, the escalating prevalence of chronic
diseases in the APAC region serves as a significant driver for the growth of
the Cell and Gene Therapy Biomanufacturing Market. With the potential to
revolutionize treatment paradigms, investment and innovation in this sector are
poised to flourish. However, realizing the full potential of the market
necessitates effective resolutions to regulatory, cost, and technical
challenges. By addressing these obstacles, the field can unlock new frontiers of
healthcare possibilities and improve patient outcomes.
Surge in Technological Advancements
The Asia Pacific (APAC) Cell and Gene Therapy
Biomanufacturing Market is experiencing a robust growth trajectory, propelled
by a remarkable surge in technological advancements. These cutting-edge
technologies are revolutionizing the development and production of cell and
gene therapies (CGTs), offering new avenues for the treatment of a wide range
of diseases.
One of the significant drivers of this market's
expansion is the escalating demand for efficient and scalable cell production.
As CGTs become increasingly sophisticated, there is a growing need for
innovative methods to produce cells in a more streamlined and scalable manner.
Technological innovations, such as advancements in bioreactors, automation, and
artificial intelligence (AI), are playing a pivotal role in meeting this
demand. These advancements are transforming the biomanufacturing process,
making it more efficient, cost-effective, and capable of producing high-quality
therapeutic products.
In conclusion, the surge in technological
advancements serves as a primary catalyst for the growth of the APAC Cell and
Gene Therapy Biomanufacturing Market. As these technologies continue to evolve
and mature, they hold immense potential to shape the future of CGT development
and production. By unlocking new possibilities and delivering more effective
treatments, these advancements promise to significantly improve patient
outcomes across a wide spectrum of diseases.
Download Free Sample Report
Key Market Challenges
Volatility in Cost of Goods and Pricing Pressures
The Asia Pacific (APAC) Cell and Gene Therapy
Biomanufacturing Market has experienced remarkable growth in recent years,
propelled by advancements in technology and the rising prevalence of chronic
diseases. This flourishing sector, however, is not without its challenges. One
of the prominent obstacles is the volatility in the cost of goods and the
mounting pressure on pricing.
Cell and gene therapies (CGTs) have opened up new
horizons in healthcare, offering potentially curative treatments for a wide
range of diseases. However, the production and delivery of these therapies
entail high levels of personalization, which result in significant costs. Moreover,
the steep price tags associated with CGTs have faced criticism from payers. The
complex biomanufacturing processes, specialized equipment requirements, and the
need for highly skilled personnel contribute to the elevated costs.
Consequently, market players are under considerable pressure to lower prices,
driven by governments and payers.
Additionally, the biotechnology sector's rapid
evolution introduces a significant challenge in terms of cost volatility. For
instance, the search for cost reductions is intensified due to Big Pharma's
limited recent R&D productivity. This unpredictability in production costs
and overall financial planning poses a challenge for companies in the APAC cell
and gene therapy biomanufacturing market.
As the APAC cell and gene therapy biomanufacturing
market continues to evolve, navigating these challenges becomes crucial for
sustainable growth and success in this dynamic industry.
Key Market Trends
Expansion of Contract Development and Manufacturing
Organizations (CDMOs)
Contract Development and Manufacturing
Organizations (CDMOs) have emerged as key players in the biopharmaceutical
industry, offering a wide range of services to support the development and
production of Cell and Gene Therapies (CGTs). These services encompass crucial
aspects such as process development, assay development, and cell therapy
manufacturing. By partnering with CDMOs, pharmaceutical companies can tap into
their specialized expertise and resources, enabling accelerated development and
production of CGTs.
The demand for CDMO services in the CGT sector has
witnessed a significant surge in recent years. This upward trend translates
into exciting opportunities for CDMO staff, who now have greater prospects for
career growth and international advancement. Moreover, the rising demand for
CDMOs is not only beneficial for the organizations themselves but also
contributes to the overall growth of the APAC Cell and Gene Therapy
Biomanufacturing Market.
Interestingly, the product segment of the market is
anticipated to be dominated by consumables, with Contract Manufacturing
Organizations (CMOs) expected to play a significant role. This highlights the
pivotal position of CDMOs in the biomanufacturing ecosystem, as they facilitate
the production of essential consumables and provide critical manufacturing
support.
However, it is crucial to acknowledge that the
expansion of CDMOs also brings along certain challenges. Regulatory compliance
remains a top priority, requiring CDMOs to adhere to stringent guidelines to ensure
the safety and efficacy of CGTs. Additionally, managing complex supply chains
and keeping pace with rapid technological advancements pose ongoing challenges
that need to be addressed effectively.
Segmental Insights
Equipment Insights
Based on the category of equipment, the bioreactors/fermenters
segment emerged as the dominant player in the Asia Pacific market for cell and gene
therapy biomanufacturing in 2022. Bioreactors and fermenters play a crucial
role in the manufacturing of cell and gene therapies (CGTs), offering
controlled environments that facilitate the cultivation of cells or
microorganisms used in the production of these advanced therapies. By providing
the necessary conditions for optimal growth and development, bioreactors and fermenters
contribute to faster process development, higher yields and quality, and
ultimately, reduced production costs. This enables researchers and
manufacturers to meet the increasing demand for CGTs while ensuring consistent
and efficient production.
Application Insights
The formulation and hydration segment is projected
to experience rapid growth during the forecast period. Formulation, in the
context of cell and gene therapies (CGTs), is a meticulous process that
involves combining various components to create a final product suitable for
patient administration. This intricate process ensures the stability and
efficacy of the therapeutic product.
CGTs are highly complex and sensitive, requiring
specialized formulation strategies to maintain their viability and
functionality. For instance, the formulation must shield the therapeutic
product from degradation during storage and transportation, guaranteeing its
stability until it reaches the patient. This aspect becomes particularly
crucial in the APAC region, where diverse geographical and climatic conditions
can potentially impact the stability of CGTs.
Moreover, hydration plays a pivotal role in the
biomanufacturing of CGTs. It contributes to several stages of the production
process, most notably in cell culture, where it fosters optimal conditions for
cell growth and proliferation.
Additionally, hydration holds significance in the
formulation process itself. For example, lyophilized (freeze-dried) products
necessitate rehydration before administration. This rehydration process demands
careful control to preserve the stability and efficacy of the final product. By
ensuring proper hydration, the formulation process maximizes the therapeutic
potential of CGTs, offering enhanced patient outcomes.
Download Free Sample Report
Regional Insights
China emerged as the dominant player in the Asia
Pacific Cell and Gene Therapy Biomanufacturing Market in 2022, holding the
largest market share in terms of value. China has emerged as a key player in
the field of biotechnology, making substantial investments in areas such as
gene and cellular therapy. With a strategic focus on "innovation
mercantilism," China adopts policies and regulations to foster domestic
innovation and reduce reliance on foreign technologies. This approach has
yielded remarkable progress in various subfields of health biotechnology,
notably in the realms of therapeutic antibodies and gene research.
In China, the biotechnology sector is predominantly
driven by biologics, encompassing cell and gene therapies. Recognizing the
immense potential of these therapies, the government has been actively funding
the development of novel cell lines and facilitating collaborations among
biotech companies. Such initiatives have created a highly conducive environment
for the rapid growth of the cell and gene therapy biomanufacturing market,
positioning China as a frontrunner in this domain.
Recent Developments
- In January 2023, Sartorius AG, a leading provider
of laboratory and process technologies, collaborated with Roosterbio Inc., a
pioneer in the field of stem cell manufacturing, to advance its downstream
purification processes for the development of exosomes. This collaboration aims
to enhance the efficiency and scalability of exosome production, ultimately
benefiting the field of regenerative medicine and drug delivery.
- In February 2022, Sartorius AG completed the
strategic acquisition of Novasep's chromatography division, a renowned player
in the purification and separation technologies market. This acquisition
complements Sartorius AG's existing product portfolio, further strengthening
its position as a leading provider of innovative solutions for bioprocessing
applications.
- In August 2022, Merck KGaA, a global science and
technology company, launched the VirusExpress 293 Adeno-Associated Virus (AAV)
Production Platform. This cutting-edge platform is designed to accelerate the
development of cell and gene therapies by providing a streamlined and efficient
production process for AAV vectors, which are crucial for the delivery of
genetic material into target cells.
- In June 2022, Lonza Group AG, a leading provider of
cell and gene therapy manufacturing solutions, and Adva Biotechnology Ltd., a
biotechnology company specializing in automated bioreactors, entered into a
license agreement. This agreement enables Adva Biotechnology to access Lonza's
core intellectual property, empowering them to expand the reach of their
automated bioreactors worldwide. This collaboration aims to advance the field
of bioprocessing and facilitate the large-scale production of biologics.
- In June 2022, Becton, Dickinson and Company (BD), a
global medical technology company, launched the FACSDiscover S8 Cell Sorter
featuring CellView Image Technology. This state-of-the-art cell sorting system
leverages advanced imaging capabilities to provide researchers with
unprecedented insights into cellular behavior and heterogeneity. The
FACSDiscover S8 Cell Sorter is poised to revolutionize single-cell analysis and
accelerate discoveries in fields such as immunology, cancer research, and
regenerative medicine.
- In January 2023, Bio-Techne Corporation, a leading
provider of life science tools and reagents, launched the RNAscope plus assay.
This innovative assay enables researchers to visualize and analyze gene
expression at the single-cell level with unparalleled sensitivity and
specificity. By advancing the field of gene therapy development, the RNAscope
plus assay has the potential to unlock new therapeutic targets and improve the
efficacy of gene-based treatments.
- In September 2021, Thermo Fisher Scientific Inc., a
global leader in scientific research and biotechnology, introduced the
integrated Gibco AAV-MAX Helper Free AAV Production System. This comprehensive
system provides researchers and biomanufacturers with a complete workflow
solution for the production of adeno-associated virus (AAV) vectors, a crucial
tool in gene therapy and vaccine development. With its streamlined and
user-friendly design, the Gibco AAV-MAX system enables efficient and high-yield
AAV vector production, facilitating breakthroughs in gene-based medicine.
Key Market Players
- Becton, Dickinson and Company
- Bio-Rad
Laboratories, Inc.
- Bio-Techne
Corporation
- Danaher
Corporation
- Endress+Hauser
Group Services AG (Analytik Jena GmbH)
- General
Electric Company
- Getinge
AB
- Infors AG
- Lonza
Group Ltd
- Merck
KGaA
|
|
By
Application
|
By Country
|
- Bioreactors/Fermenters
- Mixing
Systems
- Cell
Counters
- Cell Sorters
- Centrifuges
- Incubators
- Biosafety Cabinets
- Freezers
- PCR Systems
- Transfection
Systems
- Storage
Tanks
- Others
|
- Formulation
and Hydration
- Cell Culture
Processing
- Separation
and Filtration
- Others
|
- China
- Japan
- South Korea
- Australia
- India
- Rest of
Asia-Pacific
|
Report Scope:
In this report, the Asia Pacific Cell and Gene
Therapy Biomanufacturing Market has been segmented into the following
categories, in addition to the industry trends which have also been detailed
below:
- Asia Pacific Cell and Gene Therapy Biomanufacturing
Market, By Equipment:
o Bioreactors/Fermenters
o Mixing Systems
o Cell Counters
o Cell Sorters
o Centrifuges
o Incubators
o Biosafety Cabinets
o Freezers
o PCR Systems
o Transfection Systems
o Storage Tanks
o Others
- Asia Pacific Cell and Gene Therapy
Biomanufacturing Market, By
Application:
o Formulation and Hydration
o Cell Culture Processing
o Separation and Filtration
o Others
- Asia Pacific Cell and Gene Therapy
Biomanufacturing Market, By Country:
o China
o Japan
o South Korea
o Australia
o India
o Rest of Asia-Pacific
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Asia
Pacific Cell and Gene Therapy Biomanufacturing Market.
Available Customizations:
Asia Pacific Cell and Gene Therapy Biomanufacturing
Market report with the given Market data, Tech Sci Research offers
customizations according to a company's specific needs. The following
customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional Market
players (up to five).
Asia Pacific Cell and
Gene Therapy Biomanufacturing Market is an upcoming report to be released soon.
If you wish an early delivery of this report or want to confirm the date of
release, please contact us at [email protected]